(TheRedAlertNews.com) – In a suspicious move, the Oxford-AstraZeneca coronavirus vaccine, known as Vaxzevria, will soon be discontinued globally, a decision made mere months after the company conceded that the vaccine may lead to a rare but severe side effect – even though the producer claims it is motivated by commercial reasons.
The company has recently revoked its “marketing authorization” for Vaxzevria within the European Union and intends to follow suit in the United Kingdom and other nations where the vaccine was administered.
This action, however, will not affect the United States, as the vaccine was never approved for use there.
AstraZeneca has cited commercial reasons for this decision, pointing out that Vaxzevria’s production has ceased and that newer vaccines targeting various strains of the virus have been developed.
The company’s acknowledgment in legal documents that the vaccine may cause Thrombosis with Thrombocytopenia Syndrome (TTS) — a condition leading to blood clots and low blood platelet counts — followed the revelation of at least 81 related fatalities in the UK, as reported by The Telegraph.
In litigation involving 51 individuals claiming harm from the vaccine and seeking damages up to £100 million, AstraZeneca confirmed, “its Covid vaccine can, in very rare cases, cause TTS.”
After initial suspensions of the vaccine’s use in several European countries due to concerns over blood clot-related deaths, the European Medicines Agency in April 2021 acknowledged a “possible link” between the vaccine and unusual blood clots with low blood platelets but concluded that the vaccine’s benefits exceeded its risks.
The UK government significantly reduced its use of the AstraZeneca vaccine in the latter part of 2021 after administering approximately 50 million doses. It opted instead for Pfizer and Moderna vaccines for its winter booster campaign.
In 2023, a notable statistician pointed out an increase in cardiac deaths among young women following their first dose of non-mRNA vaccines, noting the risk was 3.5 times higher in the 12 weeks post-vaccination compared to the longer-term risk.
While billions of AstraZeneca doses were distributed to developing countries through a United Nations program due to its cost-effectiveness, many of these nations eventually transitioned to mRNA vaccine alternatives.
“To those who we represent, all of whom have suffered bereavement or serious injury as a result of the AstraZeneca vaccine, this decision to withdraw marketing authorization, ending the usage of the AstraZeneca vaccine in the EU, will be welcomed,” commented Sarah Moore from Leigh Day, the law firm representing those allegedly harmed by the vaccine in the UK.
“It will be seen as a decision linked with AstraZeneca’s recent admission that the vaccine can cause TTS, and the fact that regulators across the world suspended or stopped usage of the vaccine following concerns regarding TTS,” she added.
Copyright 2024, TheRedAlertNews.com
